Document is current
Any future updates will be listed below
-
Authors
Pizzamiglio, S.
Ciniselli, C. M.
de Azambuja, E.
Agbor-tarh, D.
Moreno-Aspitia, A.
Suter, T. M.
Trama, A.
De Santis, M. C.
De Cecco, L.
Iorio, M. V.
Silvestri, M.
Pruneri, G.
Verderio, P. https://orcid.org/0000-0002-9231-1281
Di Cosimo, S.
-
Funding
Funding for this research was provided by:
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (BRI2018)
- License Information
-
More Information
Article History
Received: 9 November 2023
Accepted: 19 February 2024
First Online: 30 April 2024
Declarations
:
: SDC received fees for medical education from Pierre Fabre, AstraZeneca, and IQVIA; the research grant IG 20774 from Fondazione Associazione Italiana Ricerca contro il Cancro (AIRC); and served as <i>“</i>ad hoc<i>”</i> medical advisor for Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain). AMA received institutional research fund from GSK, Novartis, Genentech, and Sermonix. GP received Honoraria from Roche Foundation and Exact Science; Advisory Board from ADSBIOTEC and AstraZeneca. EdA: Advisory Board from Roche/GNE, Novartis, Seagen, Zodiac, Libbs, Pierre Fabre, Lilly, and AstraZeneca; Research grant from Roche/GNE, AstraZeneca, GSK/Novartis, and Servier. AT, DAt, TMS, LDC, MVI, MS, MCDS, CMC, SP, and PV declared no competing interest.
: The studies involving human participants were reviewed and approved by Ethics Committee of Fondazione IRCCS Istituto Nazionale dei Tumori. The patients/participants provided their written informed consent to participate in this study.
